Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

HPGDS enzyme plays key role in resistance of immunotherapy in various cancers  Up to 65% of patients with melanoma do not ...

Bristol Myers Squibb today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...

A research team at the Institute for Basic Science (IBS) has identified a previously unknown enzyme, SIRT2, that plays a key ...

KANSAS CITY — Technological advancements may impact several areas in the baking industry: shelf life, nutrition, ...

Modern medicine is a field of research that is constantly evolving, driving groundbreaking discoveries that have saved ...

Total Control 24 (TC24) is a next-generation prostate health supplement created by Adem Naturals. Designed specifically for ...

Arcus Biosciences, Inc.’s RCUS share price has dipped by 5.50%, which has investors questioning if this is right time to buy.

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its ...

In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.

Unlock luminous, healthy skin naturally with tips to restore your barrier, hydrate deeply, and glow from the inside out.

Mirum Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus ...